Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 513Thoracic 190CNS 185Gynecologic 135Breast 123Genitourinary 62Sarcoma 51Dermatologic 31Tumor-Agnostic 30Head & Neck 26Other solid neoplasm 24Lymphoid 12Endocrine 12Other hematologic neoplasm 8Myeloid 5Plasma cell 4NET 4Classical hematology 2

Conditions

Neuroendocrine Tumors 4Vipoma 1Somatostatinoma 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Bevacizumab × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00398320 2017-03-01

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Completed
40 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

NCT00137774 2013-04-09

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
34 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01203306 2010-09-16

XELBEVOCT

University of Turin, Italy

Phase 2 Unknown
42 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡